

# **Biomarkers**

## **Part 1: Technologies & Applications**

**By**

**Prof. K.K. Jain**  
MD, FRACS, FFPM  
**Jain PharmaBiotech**  
**Basel, Switzerland**

**December 2017**

**A Jain PharmaBiotech Report**

## **A U T H O R ' S   B I O G R A P H Y**

Professor K. K. Jain is a neurologist/neurosurgeon by training and has been working in the biotechnology/biopharmaceuticals industry for several years. He received graduate training in both Europe and USA, has held academic positions in several countries and is a Fellow of the Faculty of Pharmaceutical Medicine of the Royal College of Physicians of UK. Currently he is a consultant at Jain PharmaBiotech. Prof. Jain's 473 publications include 28 books (5 as editor+ 23 as author) and 50 special reports, which have covered important areas in biotechnology, gene therapy and biopharmaceuticals. The following Jain PharmaBiotech reports are relevant to biomarkers: proteomics, molecular diagnostics, nanobiotechnology, and personalized medicine. Recent books include "Handbook of Nanomedicine" (Springer 2008, Chinese edition by Peking University Press 2011, 3rd ed 2017), "Textbook of Personalized Medicine" (Springer 2009; Japanese ed 2012; 2<sup>nd</sup> ed Springer 2015), "Handbook of Biomarkers" (Springer 2010; Chinese ed, Chemical Industry Press 2016, 2<sup>nd</sup> ed 2017), "Handbook of Neuroprotection" (Springer 2011), "Applications of Biotechnology in Cardiovascular Therapeutics" (Springer 2011), "Applications of Biotechnology in Neurology" (Springer 2013), and "Applications of Biotechnology in Oncology" (Springer 2014). He has also edited "Applied Neurogenomics" (Springer 2015).

December 2017  
Copyright © 2017 by

Jain PharmaBiotech  
Bläsiring 7  
CH-4057 Basel  
Switzerland

**Tel & Fax:** +4161-6924461  
**Email:** info@pharmabiotech.ch  
**Web site:** <http://pharmabiotech.ch/>

All rights reserved. No part of this publication may be reproduced, stored in a retrieval system, or transmitted in any form or by any means, electronic, mechanical, photocopying, or otherwise without the prior written permission of the Publisher. This report may not be lent, resold or otherwise traded in any manner without the consent of the Publisher. While all reasonable steps have been taken to ensure the accuracy of the information presented, the Publisher cannot accept responsibility for inadvertent errors or omissions.

# TABLE OF CONTENTS

<b>0. Executive Summary .....</b>	<b>27</b>
<b>1. Introduction .....</b>	<b>29</b>
<b>Definitions .....</b>	<b>29</b>
<b>Historical aspects of biomarkers.....</b>	<b>29</b>
<b>Classification of biomarkers.....</b>	<b>30</b>
Biomarker as a response to therapeutic intervention .....	31
Pharmacokinetic/pharmacodynamics biomarkers .....	31
Predictive biomarkers .....	31
Valid biomarkers.....	32
<b>Types of biomarkers .....</b>	<b>33</b>
Genes as biomarkers.....	33
<i>Silent gene mutations.....</i>	<i>33</i>
Epigenetic biomarkers .....	33
Proteins as biomarkers .....	34
<i>Proteomics .....</i>	<i>34</i>
DNA biomarkers .....	35
Mitochondrial DNA .....	35
<i>Mitochondrial mutations.....</i>	<i>35</i>
RNA biomarkers.....	35
<i>Transcriptomics .....</i>	<i>36</i>
<i>MicroRNAs .....</i>	<i>37</i>
Metabolomics .....	37
Glycomics .....	37
Single nucleotide polymorphisms .....	38
<i>Haplotyping.....</i>	<i>38</i>
Cell biomarkers of disease .....	39
Stem cell biomarkers.....	39
<i>Association of stem cell biomarkers with disease.....</i>	<i>39</i>
<i>Cancer stem cell biomarkers.....</i>	<i>40</i>
<i>Endoglin as a functional biomarker of stem cells .....</i>	<i>40</i>
<i>p75NTR as a biomarker to isolate adipose tissue-derived stem cells .....</i>	<i>40</i>
<i>Protein expression profile as biomarker of stem cells .....</i>	<i>40</i>
<i>STEMPRO® EZChek™ for analysis of biomarkers of hESCs .....</i>	<i>41</i>
<i>SSEA-4 as biomarker of MSCs .....</i>	<i>41</i>
Gaseous mediators as biomarkers of disease.....	41
Autoantibodies as biomarkers of autoimmune diseases.....	41
Comparison of various types of biomarkers .....	42
<b>Biomarkers and systems biology .....</b>	<b>42</b>
Systems biology approach to biomarker identification.....	44
<b>Relation of biomarkers to other technologies and healthcare .....</b>	<b>44</b>
Biomarkers and translational medicine.....	45
Role of biomarkers in monitoring of diseases.....	46
Limitations of use of biomarkers in healthcare .....	46
<b>2. Technologies for Discovery of Biomarkers .....</b>	<b>47</b>
<b>Introduction .....</b>	<b>47</b>
The ideal biomarker .....	47
<b>Genomic technologies.....</b>	<b>47</b>
Gene expression .....	47
<i>Whole genome expression array .....</i>	<i>48</i>
<i>Gene expression profiling on whole blood samples .....</i>	<i>49</i>
<i>Profiling gene expression patterns of white blood cells.....</i>	<i>49</i>
Tissue microarrays for study of biomarkers .....	49
<b>Technologies for detection of miRNAs as biomarkers .....</b>	<b>50</b>
Microarrays for analysis of miRNA gene expression .....	50
<i>Microarrays vs quantitative PCR for measuring miRNAs.....</i>	<i>51</i>
Point-of-care detection of circulating miRNAs as biomarkers.....	51
<b>Epigenomic technologies .....</b>	<b>51</b>
Discovery of methylation biomarkers.....	52
<b>Proteomic technologies .....</b>	<b>53</b>
2D GE .....	54
ProteoCarta® integrated proteomics discovery platform .....	54
Isotope-coded affinity tags.....	55
Liquid chromatography-MS/MS .....	55
Lucid Proteomics System .....	56
Magnetics beads for protein biomarker discovery .....	56
MASStermind™.....	56

Combined analysis of protein and nucleic-acid biomarkers .....	57
Mass spectrometry .....	57
2D PAGE and mass spectrometry .....	58
Imaging mass spectrometry .....	58
MALDI mass spectrometry for biomarker discovery .....	59
Quantitative tandem MS .....	59
Single-molecule mass spectrometry using a nanopore .....	60
Requirements for MS-based proteomic biomarker development .....	60
Nucleic Acid Programmable Protein Array .....	60
Protein tomography .....	61
Protein biochips/microarrays and biomarkers .....	61
Antibody array/affinity proteomics-based biomarker discovery .....	61
Detection of biomarkers using peptide array technology .....	63
ProtoArray® .....	63
Protein nanobiochip .....	63
Gene expression microarray data as a source of protein biomarkers .....	64
Quantification of protein biomarkers .....	64
Multiple reaction monitoring assays .....	64
Real-time PCR for quantification of protein biomarkers .....	65
CyTOF for quantification of biomarkers .....	65
Search for biomarkers in body fluids .....	66
Challenges and strategies for discovery of protein biomarkers in plasma .....	66
Technologies for removal of highly abundant proteins in blood .....	66
3D structure of CD38 as a biomarker .....	67
BD™ Free Flow Electrophoresis System .....	67
Isotope tags for relative and absolute quantification .....	68
Plasma protein microparticles as biomarkers .....	68
Proteome partitioning .....	69
Stable isotope tagging methods .....	69
Technology to measure both the identity and size of the biomarker .....	70
Selected reaction monitoring MS .....	70
Targeted MS for verification of biomarkers .....	70
Biomarkers in the urinary proteome .....	71
Peptides as biomarkers of disease .....	72
Analysis of peptides in bodily fluids .....	72
Antibody biomarker discovery via evolution of peptides .....	73
Serum peptidome patterns .....	73
SISCAPA method for quantitating proteins and peptides in plasma .....	74
Comparison of proteomic profiling technologies for discovery of biomarkers .....	74
Verification for interlaboratory reproducibility of protein biomarkers .....	74
Significance of similar protein biomarkers in different tissues .....	75
<b>Glycomic technologies .....</b>	<b>76</b>
Cellular glycomics for discovery of cellular biomarkers .....	76
<b>Metabolomic technologies .....</b>	<b>76</b>
Genome-wide association studies for identification of metabolic biomarkers .....	77
Genetic influences on human blood metabolites .....	77
Lipid profiling .....	78
Mass spectrometry for discovery of metabolic biomarkers in plasma .....	78
Role of metabolomics in biomarker identification and pattern recognition .....	79
Urinary profiling by capillary electrophoresis .....	79
Validation of biomarkers in large-scale human metabolomics studies .....	79
<b>Lipidomics .....</b>	<b>79</b>
<b>Disease biomarkers in breath .....</b>	<b>80</b>
Portable breath test for volatile organic compounds .....	80
Detection of breath biomarkers by sensation technology .....	81
Detection of breath biomarkers by nanosensors .....	81
Detection of breath biomarkers optical frequency comb spectroscopy .....	81
Detection of breath biomarkers by infrared absorption spectroscopy .....	82
Detection of biomarkers by electronic nose .....	82
<b>Fluorescent indicators for biomarkers .....</b>	<b>82</b>
<b>Molecular imaging technologies .....</b>	<b>83</b>
Computer tomography .....	83
Magnetic resonance imaging .....	83
Positron emission tomography .....	84
Advantages of imaging biomarkers .....	84
Monitoring in vivo gene expression by molecular imaging .....	84
Molecular imaging in vivo as a biomarker .....	85
Challenges and future of molecular imaging .....	86
Basic research in molecular imaging .....	86
Imaging intracellular NADH as a biomarker of disease .....	86
Devices for molecular imaging .....	86

<i>Imaging biomarkers in clinical trials</i> .....	86
<i>Molecular imaging in clinical practice</i> .....	87
<b>Nuclear magnetic resonance</b> .....	<b>87</b>
Chemical derivatization to enhance biomarker detection by NMR .....	87
Fluxomics by using NMR .....	88
<b>Nanobiotechnology</b> .....	<b>88</b>
Dip Pen Nanolithography.....	88
Nanomaterials for biolabeling .....	89
<i>Quantum dot molecular labels</i> .....	90
<i>Bioconjugated QDs for multiplexed profiling of biomarkers</i> .....	90
<i>Magnetic nanotags for multiplex detection of biomarkers</i> .....	90
Nanoparticles for molecular imaging.....	91
Nanoparticles for discovering biomarkers .....	91
Nanoproteomics and biomarkers.....	92
<i>High-field asymmetric waveform ion mobility mass spectrometry</i> .....	92
Nanosensors for measuring biomarkers in blood .....	92
Nanobiochip sensor technique for analysis of oral cancer biomarkers.....	92
Future prospects of application of nanobiotechnology for biomarkers.....	93
<b>Bioinformatics</b> .....	<b>93</b>
Biomarker Workflow Guide.....	93
Analysis of microarray data for selecting useful biomarkers.....	94
Role of bioinformatics in discovery of protein biomarkers .....	94
Role of bioinformatics in detection of cancer biomarkers .....	95
Biomarker databases.....	95
Gene networks as biomarkers.....	96
Role of bioinformatics in integrating various data and biomarker discovery .....	96
<b>Evaluation of biomarker studies</b> .....	<b>96</b>
<b>3. Biomarkers and Molecular Diagnostics</b> .....	<b>99</b>
<b>Introduction</b> .....	<b>99</b>
<b>Molecular diagnostic technologies</b> .....	<b>99</b>
Polymerase chain reaction.....	99
<i>Amplification</i> .....	99
<i>Target selection</i> .....	100
<i>Detection of amplified DNA</i> .....	100
<i>Limitations of PCR</i> .....	100
Real-time PCR systems.....	101
<i>Limitations of real-time PCR</i> .....	101
<i>Future applications of real-time qPCR</i> .....	102
<i>Real-time qPCR for quantification of circulating mtDNA</i> .....	102
Combined PCR-ELISA .....	102
Non-PCR methods.....	103
<i>Linked Linear Amplification</i> .....	103
Transcription mediated amplification .....	103
Rapid analysis of gene expression .....	103
WAVE nucleic acid fragment analysis system.....	104
DNA probes with conjugated minor groove binder .....	104
Rolling circle amplification technology.....	105
<i>Gene-based diagnostics through RCAT</i> .....	105
<i>RCAT-immunodiagnosics</i> .....	106
<i>RCAT-biochips</i> .....	106
<i>RCAT-pharmacogenomics</i> .....	106
Circle-to-circle amplification .....	106
Biochips and microarrays .....	107
<i>Applications of biochips/microarrays</i> .....	107
<i>Role of biochip/microarrays in discovery of biomarkers</i> .....	108
<b>Biomarkers and high throughput molecular screening</b> .....	<b>108</b>
<b>Detection and expression profiling of miRNA</b> .....	<b>109</b>
Real-time PCR for expression profiling of miRNAs.....	109
Use of LNA to explore miRNA.....	109
Microarrays for analysis of miRNA gene expression .....	109
<b>4. Biomarkers for Drug Discovery &amp; Development</b> .....	<b>111</b>
<b>Introduction</b> .....	<b>111</b>
<b>Biomarker technologies for drug discovery</b> .....	<b>111</b>
Proteomics-based biomarkers for drug discovery .....	111
Chemoproteomics .....	112
<i>Activity-based chemical proteomics</i> .....	112
Transcriptomics for drug discovery.....	112
Metabolomics for drug discovery .....	113
<b>Biomarkers and drug safety</b> .....	<b>113</b>

Biomarkers of adverse drug reactions.....	113
Applications of biomarkers in drug safety studies.....	114
Genomic technologies for toxicology biomarkers.....	114
Proteomic technologies for toxicology biomarkers.....	115
Metabonomic technologies for toxicology biomarkers.....	115
Integration of genomic and metabonomic data to develop toxicity biomarkers.....	115
Toxicology studies based on biomarkers.....	116
<i>Biomarkers of hepatotoxicity</i> .....	117
<i>Biomarkers of nephrotoxicity</i> .....	118
<i>Cardiotoxicity</i> .....	119
<i>Neurotoxicity</i> .....	120
<b>Applications of biomarkers for drug development.....</b>	<b>120</b>
Application of metabonomics/metabolomics for drug development.....	121
Application of biomarkers by the pharmaceutical companies.....	122
Biomarkers in clinical trials.....	123
<i>NIH recommendations on the use of biomarkers in clinical trials</i> .....	123
<i>Advantages of biomarkers for drug development</i> .....	124
<i>Limitations and problems with use of biomarkers in clinical trials</i> .....	125
Development of static and dynamic biomarkers.....	125
Molecular imaging as a biomarker in drug development.....	126
<i>Molecular imaging in preclinical studies</i> .....	126
<i>Molecular imaging in clinical trials</i> .....	127
<i>Prospects of molecular imaging in drug discovery and development</i> .....	128
Pharmacogenomic biomarker information in drug labels.....	128
Role of biomarkers in vaccine development.....	129
Role of biomarkers in relation to stage of drug discovery and development.....	129
Role of pharmacokinetic/pharmacodynamic biomarkers in drug development.....	129
Role of biomarkers for drug development in cardiovascular disorders.....	130
Role of biomarkers for drug development in neurological disorders.....	131
Significance of biomarkers in drug development.....	131
<b>Organizations &amp; resources for biomarker-based drug development.....</b>	<b>131</b>
Biomarker Alliance.....	132
Biomarkers Consortium.....	132
Molecular Libraries and Imaging Roadmap of NIH.....	133
Rare Diseases Clinical Research Consortia.....	134
<b>Future of biomarker-based drug development.....</b>	<b>134</b>
<b>5. Role of Biomarkers in Healthcare.....</b>	<b>137</b>
<b>Introduction.....</b>	<b>137</b>
<b>Biomarkers of inflammation.....</b>	<b>138</b>
ESR and CRP as biomarkers of inflammation.....	138
Metabolic biomarkers of inflammation.....	139
YKL-40 as a biomarker inflammation and predictor of mortality.....	139
<b>Biomarkers of allergic disorders.....</b>	<b>139</b>
<b>Biomarkers of oxidative stress.....</b>	<b>140</b>
1,4-dihydroxynonane-mercaptopic acid.....	140
Oxidized phospholipids.....	140
Oxidative DNA damage.....	141
Proteins as biomarkers of oxidative stress in diseases.....	141
Testing for oxidative stress.....	141
<b>Biomarkers of hypoxia.....</b>	<b>142</b>
Pathophysiology of hypoxia.....	142
Hypoxia inducible factor as biomarker of hypoxia and response to oxygenation.....	142
Identification of hypoxia biomarkers from exhaled breath.....	142
Metabolic biomarkers of hypoxia.....	143
<b>Biomarkers of liver disease.....</b>	<b>143</b>
Breath biomarkers of liver disease.....	143
Biomarkers of liver injury.....	143
Fibrosis and cirrhosis of liver.....	144
FibroMax.....	144
Hepatic encephalopathy.....	144
miRNA biomarkers of liver disease.....	145
Viral hepatitis B and C.....	145
<i>Biomarkers of hepatitis C</i> .....	145
<i>Biomarkers of hepatitis B</i> .....	146
<b>Biomarkers of pancreatitis.....</b>	<b>146</b>
<b>Biomarkers of renal disease.....</b>	<b>147</b>
Biomarkers of lupus nephritis.....	147
Biomarkers of diabetic nephropathy.....	148
Cystatin C as biomarker of glomerular filtration rate (GFR).....	148
Estimated GFR and albuminuria as biomarkers of chronic kidney disease.....	148

Proteomic biomarkers of acute kidney injury .....	149
Symmetric dimethylarginine as biomarker of chronic kidney disease in dogs .....	149
Troponin-T as a biomarker for predicting end-stage renal disease .....	149
<b>Biomarkers in pediatrics .....</b>	<b>149</b>
Pediatric critical care .....	149
Biomarkers of acute kidney injury in children .....	150
<b>Biomarkers of miscellaneous disorders.....</b>	<b>150</b>
Biomarkers of carbon monoxide poisoning .....	150
Biomarkers of Castleman disease.....	150
Biomarkers of erectile dysfunction.....	151
Biomarkers of fever.....	151
Biomarkers of heat stroke .....	152
Biomarkers of hyponatremia .....	152
Biomarkers of inflammatory bowel disease.....	152
Biomarkers of radiation injury .....	153
Biomarkers for prediction of all-cause mortality .....	154
Biomarkers common to multiple diseases.....	154
Nasal nitric oxide as a biomarker of response to rhinosinusitis therapy .....	155
<b>Biomarkers of gene-environmental interactions in human disease.....</b>	<b>155</b>
<b>Application of biomarkers in animal health.....</b>	<b>156</b>
<b>6. Biomarkers in Metabolic Disorders .....</b>	<b>159</b>
Biomarkers of acute intermittent porphyria .....	159
Liver X receptors .....	159
Biomarkers of diabetes mellitus .....	159
<i>β-cell function as biomarker of diabetes.....</i>	<i>161</i>
<i>Biomarkers of hyperglycemia .....</i>	<i>161</i>
<i>Biomarkers of diabetes-associated oxidative stress .....</i>	<i>161</i>
<i>Biomarkers of inflammation associated with diabetes .....</i>	<i>161</i>
<i>Biomarkers of renal complications in diabetes mellitus type 2.....</i>	<i>162</i>
<i>Biomarkers of diabetes .....</i>	<i>162</i>
<i>Biomarkers of prediabetes.....</i>	<i>162</i>
<i>Biomarkers of insulin resistance.....</i>	<i>162</i>
<i>Glycosylated hemoglobin in diabetes mellitus .....</i>	<i>163</i>
<i>Glycated albumin as a biomarker of diabetes mellitus.....</i>	<i>163</i>
<i>Low C-peptide as a biomarker of complications of diabetes type 1.....</i>	<i>163</i>
<i>Personalized management of diabetes mellitus based on biomarkers.....</i>	<i>164</i>
Biomarkers of metabolic syndrome .....	164
<i>Adiponectin.....</i>	<i>164</i>
<i>Cystatin C.....</i>	<i>165</i>
<i>Human plasma lipidome.....</i>	<i>165</i>
<i>Neurotensin as biomarker of obesity.....</i>	<i>166</i>
<b>7. Biomarkers in Immune Disorders .....</b>	<b>169</b>
<b>Introduction .....</b>	<b>169</b>
<b>Biomarkers relevant to organ transplantation .....</b>	<b>169</b>
Biomarkers of graft versus host disease.....	169
Biomarkers of renal allograft failure .....	170
Biomarkers of renal transplant tolerance.....	171
Biomarkers of lung transplant rejection .....	172
Biomarkers of GVHD following transplantation of hematopoietic cells.....	172
Plasma biomarkers of response to therapy of GVHD .....	172
<b>Systemic lupus erythematosus .....</b>	<b>173</b>
Adiponectin as biomarker of SLE.....	173
Current management and need for biomarkers of SLE .....	173
Role of collaborative efforts and databases of SLE biomarkers .....	174
C4d-bearing reticulocytes .....	174
CB-CAPS.....	174
Epigenetic biomarkers of SLE .....	174
Genetic loci of SLE .....	175
HMGB1 .....	175
<b>Biomarkers of systemic sclerosis.....</b>	<b>175</b>
<b>8. Biomarkers of Musculoskeletal Disorders .....</b>	<b>177</b>
<b>Introduction .....</b>	<b>177</b>
<b>Muscle disorders.....</b>	<b>177</b>
Biomarkers of muscle fatigue during exercise .....	177
Biomarkers of mitochondrial content in skeletal muscle .....	177
Idiopathic inflammatory myopathies.....	178
<b>Rheumatoid arthritis.....</b>	<b>178</b>
Assays for biomarkers of RA.....	179

Biomarkers for personalizing therapy of rheumatoid arthritis .....	179
Circulating cytokines in RA .....	180
Epigenetic biomarkers of rheumatoid arthritis .....	180
miRNA biomarkers in RA .....	180
Serum CRP in RA .....	181
<b>Biomarkers of spondylarthritis .....</b>	<b>181</b>
Biomarkers of axial spondyloarthritis .....	182
Biomarkers of psoriatic arthritis .....	182
<b>Osteoarthritis .....</b>	<b>182</b>
Molecular pathophysiology of OA .....	183
Biomarkers of osteoarthritis .....	183
Assays for biomarkers of OA .....	184
Biomarkers of OA .....	184
Concluding remarks and future prospects of biomarkers of OA .....	185
<b>Biomarkers of osteoporosis .....</b>	<b>185</b>
Assays for detection of biomarkers of osteoporosis .....	185
Bone imaging with quantitative CT and MRI .....	186
Circulating miRNAs as biomarkers of osteoporosis .....	186
Dual x-ray absorptiometry .....	187
Utility of biomarkers of osteoporosis .....	187
<b>Biomarkers of osteonecrosis .....</b>	<b>187</b>
Osteonecrosis in Gaucher's disease .....	187
<b>9. Biomarkers of Infectious Diseases .....</b>	<b>189</b>
<b>Introduction .....</b>	<b>189</b>
<b>Technologies for discovery of biomarkers of infection .....</b>	<b>189</b>
Chemokines as biomarkers of infection .....	189
Endotoxin as biomarker of infection .....	189
Proteomics for discovering biomarkers of infections .....	189
Soluble urokinase plasminogen activator receptor .....	190
<b>Sepsis .....</b>	<b>190</b>
Biomarkers of sepsis .....	191
<i>Circulating CPS-1 as biomarkers of organ damage in sepsis .....</i>	<i>192</i>
<i>CoQ10 level reduction in septic shock .....</i>	<i>192</i>
<i>Multibiomarker-based outcome risk stratification of septic shock .....</i>	<i>193</i>
<i>Nitric oxide as a biomarker of sepsis .....</i>	<i>193</i>
<i>SuPAR as a biomarker of sepsis .....</i>	<i>193</i>
Systemic inflammatory response syndrome .....	194
<b>Tuberculosis .....</b>	<b>194</b>
Conventional diagnosis of tuberculosis .....	195
Molecular diagnostics for tuberculosis .....	195
Biomarkers for tuberculosis .....	195
Biomarkers of pulmonary tuberculosis in the breath .....	196
<b>Biomarkers of viral infections .....</b>	<b>196</b>
Viral hepatitis .....	196
Biomarkers of SARS .....	198
Biomarkers of HIV .....	199
<b>Biomarkers in parasitic infections .....</b>	<b>200</b>
Role of biomarkers in malaria .....	200
Identification of biomarkers in Schistosomiasis infections .....	200
<b>Diagnostic &amp; therapeutic applications of biomarkers of infections .....</b>	<b>201</b>
Biomarkers to discriminate bacterial from nonbacterial respiratory infections .....	201
Procalcitonin as a guide to antibiotic therapy in infections .....	201
<b>10. Biomarkers of Genetic Disorders .....</b>	<b>203</b>
<b>Introduction .....</b>	<b>203</b>
<b>Biomarkers of Down's syndrome .....</b>	<b>203</b>
<b>Biomarkers of muscular dystrophy .....</b>	<b>203</b>
<b>Biomarkers of phenylketonuria .....</b>	<b>204</b>
<b>Genetic biomarkers of psoriasis .....</b>	<b>204</b>
<b>Biomarkers of lysosomal storage disorders .....</b>	<b>205</b>
Biomarkers of Niemann-Pick disease .....	205
<i>Bile acids as biomarkers for the early diagnosis of NPD .....</i>	<i>205</i>
<i>Cholesterol oxidation products as biomarkers of NPD .....</i>	<i>205</i>
Biomarkers of mucopolysaccharidoses .....	206
<i>Proteomic technologies for biomarkers of MPS .....</i>	<i>206</i>
<i>Glycan-based biomarkers for MPS .....</i>	<i>207</i>
<i>Biomarkers of LSD .....</i>	<i>207</i>
<i>Prenatal diagnosis of LSD .....</i>	<i>207</i>
Biomarkers of Fabry's disease .....	208



<b>11. Biomarkers of Aging .....</b>	<b>209</b>
<b>Introduction .....</b>	<b>209</b>
<b>Biomarkers of biological age.....</b>	<b>210</b>
<b>Gene variants as determinants of biological age.....</b>	<b>211</b>
Gene expression profiles for calculating transcriptomic age .....	211
<b>Biomarkers of healthy aging .....</b>	<b>211</b>
<b>Biomarkers of longevity.....</b>	<b>212</b>
Healthy aging index .....	212
Effect of calorie restriction on biomarkers of longevity .....	212
<b>Biomarkers as predictors of mortality with aging .....</b>	<b>212</b>
Genetic biomarkers of aging.....	213
Genetic signatures of longevity.....	213
<b>Low serum thyroid hormone level as biomarker of longevity.....</b>	<b>213</b>
<b>Metabolomic biomarkers of aging .....</b>	<b>214</b>
<b>Mitochondrial mutations as biomarkers of aging .....</b>	<b>214</b>
<b>Protein biomarkers of aging .....</b>	<b>214</b>
Carbamylated proteins as biomarkers of aging .....	214
Proteomic biomarkers of muscle aging.....	215
Role of humanin in age-related diseases .....	215
<b>Role of bioinformatics in search for biomarkers of aging .....</b>	<b>215</b>
<b>Aging biomarkers in a genetically homogeneous population .....</b>	<b>216</b>
<b>Telomere attrition as aging biomarker.....</b>	<b>216</b>
<b>12. Nutritional Biomarkers .....</b>	<b>217</b>
<b>Introduction .....</b>	<b>217</b>
<b>Biomarkers of Nutrition for Development project .....</b>	<b>217</b>
<b>Biomarkers in nutritional epidemiology .....</b>	<b>217</b>
<b>Biomarkers of nutritional status .....</b>	<b>218</b>
Ferritin as biomarker of nutritional status.....	218
Folate biomarkers related to nutritional health status .....	219
Iodine as biomarker of nutritional status.....	219
Zinc as a biomarker of nutritional status .....	220
<b>Biomarkers of branched chain amino acid status.....</b>	<b>220</b>
<b>Biomarkers of caloric restriction.....</b>	<b>220</b>
<b>Biomarkers of malnutrition.....</b>	<b>220</b>
Maternal nutrition during early pregnancy causes epigenetic changes .....	221
<b>Proteomic biomarkers and nutrition .....</b>	<b>221</b>
<b>Vitamin deficiency as biomarker of disease .....</b>	<b>221</b>
Vitamin A biomarkers .....	221
Vitamin B12 deficiency .....	222
Vitamin D deficiency as a biomarker of disease.....	223
<b>Role of biomarkers in the development of personalized nutrition.....</b>	<b>223</b>
<b>13. Biomarkers of Cancer.....</b>	<b>225</b>
<b>Introduction .....</b>	<b>225</b>
The ideal biomarker for cancer .....	225
Biomarkers and hallmarks of cancer .....	226
Single vs multiple biomarkers of cancer .....	226
<b>Types of cancer biomarkers .....</b>	<b>227</b>
miRNAs as biomarkers in cancer .....	227
<i>Diagnostic value of miRNA in cancer.....</i>	<i>229</i>
Biomarkers of epigenetic gene silencing in cancer .....	229
<i>5-hydroxymethylcytosine as a biomarker of cancer .....</i>	<i>230</i>
Carcinoembryonic antigen .....	230
Circulating cancer biomarkers.....	230
<i>Circulating tumor cells as cancer biomarkers.....</i>	<i>230</i>
<i>Circulating nucleic acids as potential biomarkers of cancer .....</i>	<i>231</i>
<i>Circulating exosomes and microvesicles as biomarkers of cancer .....</i>	<i>231</i>
<i>Circulating miRNAs for cancer detection.....</i>	<i>232</i>
DNA repair biomarkers .....	232
HER3 as biomarker of cancer.....	232
Immunologic and inflammation biomarkers of cancer .....	232
Metastatic cancer biomarkers .....	233
<b>Molecular diagnostic techniques for cancer .....</b>	<b>233</b>
<b>Technologies for detection of cancer biomarkers.....</b>	<b>235</b>
Genomic technologies for cancer biomarkers .....	235
<i>Biomarkers of PTEN tumor suppressor gene status.....</i>	<i>235</i>
<i>Cold-PCR .....</i>	<i>235</i>
<i>ddPCR for detection of cancer biomarkers in cell free plasma DNA.....</i>	<i>236</i>
<i>Digital karyotyping for cancer biomarkers .....</i>	<i>236</i>
<i>Genome analysis at the molecular level .....</i>	<i>236</i>

<i>KRAS</i> as a biomarker of cancer .....	237
<i>LigAmp</i> for detection of gene mutations in cancer .....	237
Mitochondrial DNA as a cancer biomarker.....	237
Next generation sequencing for detection of cancer biomarkers.....	238
Telomerase as a biomarker of cancer .....	239
Tissue microarrays for study of cancer biomarkers .....	239
Molecular fingerprinting of cancer .....	240
Proteomic technologies for detecting biomarkers of cancer .....	240
2D PAGE.....	241
Antibody-based detection of protein biomarkers .....	241
Aptamer-based molecular probes for cancer biomarker discovery.....	242
Biomarkers of protein-drug interactions in cancer .....	242
Cancer immunomics to identify autoantibody signatures .....	243
Desorption electrospray ionization for detection of cancer biomarkers.....	243
Detection of circulating nucleosomes in serum of cancer patients.....	243
Detection of tumor biomarkers with ProteinChip technology .....	244
Glycoprotein biomarkers of cancer .....	244
HER-2/ <i>neu</i> oncoprotein as biomarkers for cancer .....	244
Humoral proteomics.....	245
Laser capture microdissection.....	245
Membrane-type serine protease-1.....	245
Proteomic analysis of cancer cell mitochondria.....	246
Proteomic technologies for detection of autoimmune biomarkers .....	246
SELDI-TOF MS.....	247
Serum proteome analysis for early detection of cancer .....	247
Synthetic biomarker-based POC diagnostic for cancer.....	247
Triple-quadrupole MS for detection of mutant proteins.....	247
Targeted MS for validation of cancer biomarkers in plasma .....	248
Tissue proteomics for discovery of cancer biomarkers.....	248
VeraTag system for cancer biomarkers .....	248
Metabolomic biomarkers of cancer .....	248
Magnetic resonance for detecting metabolomics biomarkers of cancer .....	249
Choline phospholipid biomarkers of cancer .....	249
Hypoxia-inducible factor-1 .....	249
Detection of drug resistance in cancer by metabolic profiling .....	250
Plasma free amino acids profiling in cancer .....	250
Urinary metabolomic biomarkers of cancer.....	251
Epitomics for the early detection of cancer .....	251
Epigenetic biomarkers of cancer .....	251
Detection of biomarkers of DNA methylation .....	252
Epigenomics Marker Machine for DNA methylation biomarkers.....	253
Histone deacetylase .....	253
MDSca <sup>TM</sup> microarray technology .....	253
Mucins as epigenetic biomarkers in epithelial cancers .....	254
PCR with bisulfite for detecting DNA methylation biomarkers in cancer .....	254
Detection of methylated DNA in serum and urine .....	255
Integrated platform for genetic and epigenetic analysis .....	255
Nanobiotechnology for early detection of cancer to improve treatment .....	256
Aptasensor for electrochemical detection of exosomes.....	256
Nanowire biosensors for detection of cancer biomarkers .....	256
NP-peptide complexes for detection of cancer biomarkers in urine.....	257
Ultrasound radiation to enhance release of a tumor biomarker .....	257
In vivo imaging of cancer biomarkers .....	258
Computer tomography.....	258
Optical systems for in vivo molecular imaging of cancer.....	258
Positron emission tomography.....	258
Imaging of tumor oxygenation and microvascular permeability by MRI .....	259
Xenon-enhanced MRI .....	259
Kallikrein gene family and cancer biomarkers .....	259
Detection of CTCs as biomarkers of cancer.....	260
<b>Applications of cancer biomarkers .....</b>	<b>261</b>
Use of biomarkers for cancer classification .....	261
Cancer classification using microarrays .....	261
Proteomic classification of cancer.....	261
Use of biomarkers for early detection of cancer .....	261
Applications of biomarkers for cancer diagnosis .....	262
Methylated DNA sequences as cancer biomarkers .....	262
MicroRNA expression profiling for diagnosis of human cancers .....	263
MUC4 as a diagnostic biomarker in cancer.....	263
Applications of biomarkers for cancer diagnosis and therapy .....	263
ARTS as a biomarker as well as a basis of anticancer drugs.....	265

<i>Asparagine synthetase as biomarker for therapy with L-asparaginase</i> .....	265
<i>Peptide-based agents for targeting cancer biomarkers</i> .....	266
<i>PI3K mutations as a biomarker for use as a companion diagnostic</i> .....	266
Biomarkers for assessing efficacy of cancer therapy.....	266
<i>ERCC1-XPF expression as a biomarker of response to chemotherapy</i> .....	266
<i>P53 expression level as biomarker of efficacy of cancer gene therapy</i> .....	266
Biomarkers of angiogenesis for developing antiangiogenic therapy.....	267
<i>Biomarkers of response to antiangiogenic agents</i> .....	267
<i>Circulating endothelial cells as targets for antiangiogenic drugs</i> .....	267
<i>Imaging biomarkers for evaluation of antiangiogenic agents</i> .....	268
<i>Tumor endothelial biomarkers</i> .....	268
<i>VEGF signaling inhibitors as biomarkers</i> .....	269
<i>VEGF-PET imaging for analysis of angiogenic changes within a tumor</i> .....	269
Biomarkers of prognosis in cancer treatment.....	269
Biomarkers for monitoring cancer therapy.....	270
Biomarkers of drug resistance in cancer.....	270
<i>A systems approach to biomarkers of innate drug resistance</i> .....	270
<i>Epithelial membrane protein-1 as a biomarker of gefitinib resistance</i> .....	271
<i>Methylation biomarkers of drug resistance in cancer</i> .....	271
<i>STAT3 and resistance to cisplatin</i> .....	271
Biomarkers of radiation therapy for cancer.....	271
<b>Role of biomarkers in drug development in oncology</b> .....	<b>272</b>
Biomarker-based approval of an anticancer drug regardless of site.....	273
Biomarkers in plucked hair for assessing cancer therapy.....	273
Met receptors as targets for anticancer drugs.....	274
Molecular imaging of tumor as a guide to drug development.....	274
<i>Use of PET and SPECT to assess response to anticancer drugs</i> .....	274
<i>Use of MRI to assess response to anticancer drugs</i> .....	275
Role of biomarkers in phase I clinical trials of anticancer drugs.....	275
Safety biomarkers in oncology studies.....	276
<b>Biomarkers according to organ/type of cancer</b> .....	<b>276</b>
Bladder cancer biomarkers.....	276
<i>Detection of FGFR3 mutations in urine for diagnosis of bladder cancer</i> .....	276
<i>NMP22 BladderChek</i> .....	277
<i>Urinary telomerase as biomarker for detection of bladder cancer</i> .....	277
<i>Concluding remarks about biomarkers of urinary cancer</i> .....	277
Brain tumor biomarkers.....	277
<i>14-3-3zeta positive expression as a prognostic biomarker for GBM</i> .....	278
<i>ALDH1A3 as a biomarker of GBM</i> .....	278
<i>Biomarkers to predict response to EGFR inhibitors</i> .....	278
<i>Biomarkers for predicting recurrence of meningiomas</i> .....	279
<i>CD133 as biomarker of resistance to radiotherapy</i> .....	279
<i>Circulating microvesicles as biomarkers</i> .....	279
<i>CSF attractin as a biomarker of malignant astrocytoma</i> .....	279
<i>ELTD1 as a biomarker of gliomas</i> .....	280
<i>Methylation profiling of brain tumors</i> .....	280
<i>Metabolite biomarkers of brain tumors</i> .....	281
<i>miRNAs as biomarkers of brain tumors</i> .....	282
<i>MRI biomarker for response of brain tumor to therapy</i> .....	282
<i>Multigene predictor of outcome in GBM</i> .....	282
<i>Neuroimaging biomarkers combined with DNA microarray analysis</i> .....	283
<i>Proteomic analysis of CSF for identification of biomarkers for gliomas</i> .....	283
<i>Receptor protein tyrosine phosphatase <math>\beta</math> as biomarker of gliomas</i> .....	283
<i>Serum protein fingerprinting</i> .....	283
<i>VEGF-R2 as biomarker of angiogenesis in brain tumors</i> .....	284
<i>Future prospects of biomarkers of malignant gliomas</i> .....	284
Bone tumor biomarkers.....	284
<i>Cytogenetics for the study of bone and soft tissue tumors</i> .....	284
<i>Biomarkers of Ewing's tumors</i> .....	285
<i>Role of biomarkers in the diagnosis of bone tumors</i> .....	285
Breast cancer biomarkers.....	285
<i>Autoantibody biomarkers of breast cancer</i> .....	286
<i>Biomarkers of breast cancer in breath</i> .....	287
<i>Biomarkers for breast cancer in nipple aspiration fluid</i> .....	287
<i>Circulating tumor DNA as biomarker of breast cancer</i> .....	288
<i>Circulating exosomes as biomarkers of breast cancer</i> .....	288
<i>Flow cytometry for quantification of biomarker expression patterns</i> .....	288
<i>Plasma proteomics for biomarkers of breast cancer</i> .....	289
<i>Quantitative realtime PCR assays for biomarker validation</i> .....	289
<i>Cdk6 as a biomarker of breast cancer</i> .....	290
<i>Centromere protein-F</i> .....	290

Carbonic anhydrase IX.....	290
COX-2 as a biomarker of breast cancer.....	290
G88 as a biomarker of progression of ER+ breast cancer.....	291
Glycomic biomarkers of breast cancer.....	291
HER-2/neu oncoprotein.....	291
High mobility group protein A2.....	292
Hypermethylated genes as biomarkers of metastatic breast cancer.....	293
Lipocalin 2 as biomarker of breast cancer progression.....	293
Long intervening non-coding RNAs.....	293
Mammaglobin.....	294
miRNA biomarkers of breast cancer.....	294
p27 expression as biomarker for survival after chemotherapy.....	295
Podocalyxin.....	295
Proneurotensin and Proenkephalin.....	295
Proliferating cell nuclear antigen.....	296
Protein kinase C as a predictive biomarker of metastatic breast cancer.....	296
Retinoblastoma tumor suppressor gene as a biomarker.....	296
Riboflavin carrier protein.....	296
Risk of invasive cancer after diagnosis of ductal carcinoma in situ.....	297
Serum CA 15-3 as biomarker of prognosis in advanced breast cancer.....	297
Stage-specific embryonic antigen-3.....	297
Suppressor of deltex protein.....	298
Tumor microenvironment as biomarker of metastasis in breast cancer.....	298
Type III TGF- $\beta$ receptor as regulator of cancer progression.....	298
Diagnostic tests based on breast cancer genes.....	299
Prognostic role of breast cancer genes.....	299
Protein biomarkers for breast cancer prevention.....	300
Biomarkers to evaluate efficacy of chemoprevention.....	300
Biomarkers of response to chemotherapy of breast cancer.....	301
Biomarker-guided decisions for breast cancer therapy.....	301
Concluding remarks and future prospects of breast cancer biomarkers.....	301
Cervical cancer biomarkers.....	302
Gastrointestinal cancer biomarkers.....	303
Esophageal cancer biomarkers.....	303
Gastric cancer biomarkers.....	303
Colorectal cancer biomarkers.....	304
Head and neck cancer.....	310
Leukemia biomarkers.....	312
Chromosome translocations in leukemias.....	312
DNA methylation biomarkers in leukemia.....	313
Gene mutations as biomarkers in leukemia.....	313
Molecular diagnostic techniques for leukemia.....	313
Proteomic technologies for discovering biomarkers of leukemia.....	314
Biomarkers of chronic lymphocytic leukemia.....	314
Biomarkers of chronic myeloid leukemia.....	315
Biomarkers of drug resistance in leukemia.....	315
Biomarkers of myelodysplastic syndromes.....	316
Lymphoma biomarkers.....	316
Liver cancer biomarkers.....	316
Biomarkers indicating lower risk of HCC in coffee drinkers.....	317
Metabonomic profiles discriminate HCC from liver cirrhosis.....	317
Urinary biomarkers of HCC.....	318
Lung cancer biomarkers.....	318
Autoantibodies as biomarkers in lung cancer.....	319
Biomarkers associated with neuroendocrine differentiation in NSCLC.....	320
Biomarkers of chronic inflammation in lung cancer.....	320
Biomarkers for predicting sensitivity to chemotherapy in lung cancer.....	320
Biomarkers for prediction of sensitivity to EGFR inhibitors.....	321
CTCs as biomarkers of lung cancer.....	322
Genomic biomarkers of lung cancer.....	322
Methylation biomarkers of lung cancer.....	323
miRNA biomarkers in lung cancer.....	323
Noninvasive detection of lung cancer using exhaled breath.....	324
Serum protein biomarkers of lung cancer.....	324
tNOX as biomarker of lung cancer.....	326
Tumor-derived DNA and RNA markers in blood.....	326
Volatile organic compounds in the exhaled breath.....	326
Malignant pleural mesothelioma.....	326
Melanoma biomarkers.....	327
Nasopharyngeal carcinoma biomarkers.....	328
Proteomic biomarkers of nasopharyngeal cancer.....	329

<i>miRNA biomarkers of nasopharyngeal carcinoma</i> .....	330
Oral cancer biomarkers.....	330
Ovarian cancer biomarkers.....	330
<i>3D microfluidic platform to assess multiple ovarian cancer biomarkers</i> .....	331
<i>CA125 as biomarker of ovarian cancer</i> .....	332
<i>Epitomics approach for ovarian cancer biomarkers in serum</i> .....	332
<i>FGF18 as a biomarker in ovarian cancer</i> .....	332
<i>Gene expression studies in ovarian cancer</i> .....	333
<i>HE4 protein in urine as a biomarker for ovarian cancer</i> .....	333
<i>Hematogenous metastasis of ovarian cancer</i> .....	333
<i>HtrA1 as a biomarker of response to chemotherapy in ovarian cancer</i> .....	334
<i>Mutation of genes in ovarian cancer</i> .....	334
<i>Serum biomarkers of ovarian cancer prognosis</i> .....	334
<i>TIM-3 as a biomarker of ovarian cancer</i> .....	335
<i>Multiplex assays for biomarkers of ovarian cancer</i> .....	335
<i>Concluding remarks on biomarker-based tests of ovarian cancer</i> .....	336
Pancreatic cancer biomarkers .....	336
<i>Discovery and validation of pancreatic cancer biomarkers</i> .....	337
<i>Cancer stem cells as biomarkers of pancreatic cancer</i> .....	337
<i>Circulating exosomes as biomarkers of pancreatic cancer</i> .....	337
<i>Histone modifications used as biomarkers in pancreatic cancer</i> .....	338
<i>miRNA biomarkers of pancreatic cancer</i> .....	338
<i>Macrophage inhibitory cytokine-1 as biomarker of pancreatic cancer</i> .....	339
<i>Proteomic biomarkers of pancreatic cancer</i> .....	339
<i>Concluding remarks on biomarkers of pancreatic cancer</i> .....	340
Parathyroid cancer biomarkers .....	340
Peripheral nerve tumors .....	340
<i>Biomarkers of neurofibromatosis</i> .....	340
Prostate cancer.....	341
<i>Adipose tissue-derived biomarkers of obesity-related prostate cancer</i> .....	342
<i>B7-H3 as biomarker of prostate cancer</i> .....	342
<i>Cancer genetics-guided biomarker signatures of prostate cancer</i> .....	342
<i>Detection of prostate cancer biomarkers in urine</i> .....	342
<i>Detection of prostatic intraepithelial neoplasia</i> .....	343
<i>Epigenetic biomarkers of prostate cancer</i> .....	344
<i>Exosomes as biomarkers of prostate cancer</i> .....	344
<i>Gene expression analysis of prostate cancer</i> .....	345
<i>Genetic biomarkers of prostate cancer</i> .....	345
<i>Identification of prostate cancer mRNA biomarkers</i> .....	346
<i>Kallikreins as biomarkers of prostate cancer</i> .....	346
<i>LCM for diagnosis of prostate cancer</i> .....	346
<i>Microarray for diagnosis of prostate cancer</i> .....	347
<i>miRNA biomarkers of prostate cancer</i> .....	347
<i>Prostate cancer biomarkers in semen</i> .....	348
<i>PSA as biomarker of prostate cancer</i> .....	349
<i>ProPSA as biomarker of prostate cancer</i> .....	349
<i>Prostate Health Index</i> .....	349
<i>Prostasomes in blood as biomarker of prostate cancer</i> .....	350
<i>PSMA as biomarker of prostate cancer</i> .....	350
<i>Sarcosine as a metabolic biomarker of prostate cancer</i> .....	350
<i>Silenced CDH13 gene as a biomarker of cancer</i> .....	350
<i>Serum-protein fingerprinting</i> .....	351
<i>Concluding remarks on biomarkers of prostate cancer</i> .....	351
Renal cancer biomarkers.....	351
<i>Gene expression profile of RCC for biomarkers</i> .....	352
<i>miRNA biomarkers of renal cancer</i> .....	352
<i>Use of proteomics for detection of RCC biomarkers</i> .....	352
<i>Use of RCC biomarkers for prognosis and therapy</i> .....	353
Thyroid cancer biomarkers .....	354
<i>Detection of BRAF mutation</i> .....	354
<i>Gene expression biomarkers of thyroid cancer</i> .....	354
<i>miRNA biomarkers of thyroid cancer</i> .....	354
<i>Multiple endocrine neoplasia type 2B as risk factor for thyroid cancer</i> .....	355
<b>Role of the NCI in cancer biomarkers</b> .....	<b>355</b>
<b>Future prospects for cancer biomarkers</b> .....	<b>356</b>
Cancer biomarker research at academic institutions .....	356
Future challenges in the discovery of cancer biomarkers .....	357

<b>14. Biomarkers of Disorders of the Nervous System</b> .....	<b>359</b>
<b>Introduction</b> .....	<b>359</b>
<b>Discovery of biomarkers for neurological disorders</b> .....	<b>359</b>

Biomarker identification in the CSF using proteomics .....	360
Biomarker identification in the CSF using lipidomics .....	360
Cerebral microdialysis for the study of biomarkers of cerebral metabolism .....	361
Detection of protein biomarkers of CNS disorders in the blood .....	361
Genomic technologies for study of biomarkers of neurological disorders.....	361
Brain imaging for detection of biomarkers .....	362
<b>Biomarkers of the aging brain .....</b>	<b>362</b>
Cellular biomarker of aging of the brain .....	362
CSF F2-isoprostanes as biomarker of aging brain .....	362
IL-6 as a biomarker of cognitive impairment with aging .....	363
Protein aggregation as a biomarker of aging brain.....	363
Telomere shortening as a biomarker of aging brain and dementia .....	363
<b>Data mining for biomarkers of neurological disorders .....</b>	<b>364</b>
<b>Antibodies as biomarkers in disorders of the nervous system .....</b>	<b>364</b>
<b>Biomarkers of neural regeneration .....</b>	<b>364</b>
<b>Biomarkers of disruption of blood-brain barrier.....</b>	<b>365</b>
<b>Biomarkers of neuroinflammation .....</b>	<b>365</b>
<b>Biomarkers of neurotoxicity.....</b>	<b>366</b>
Glial fibrillary acidic protein as biomarker of neurotoxicity .....	367
Single-stranded DNA as a biomarker of neuronal apoptosis .....	367
<b>Biomarkers of neurogenetic disorders .....</b>	<b>367</b>
Charcot-Marie Tooth disease .....	368
Duchenne and Becker muscular dystrophy .....	368
Early-onset torsion dystonia .....	369
Fragile X syndrome .....	369
Genetic neurotransmitter disorders .....	370
Hereditary neuropathy with liability to pressure palsies.....	370
Hereditary metabolic storage disorders with neurologic manifestations .....	371
<i>Gaucher disease</i> .....	371
<i>Pompe's disease</i> .....	371
Mitochondrial disorders affecting the nervous system .....	371
Spinal muscular atrophy .....	372
<i>Biomarkers of SMA</i> .....	372
<b>Biomarkers of neurodegenerative disorders .....</b>	<b>372</b>
<b>Biomarkers of dementia.....</b>	<b>373</b>
Biomarkers of vascular dementia .....	373
<b>Biomarkers of Alzheimer's disease .....</b>	<b>374</b>
The ideal biomarker for AD.....	376
Methods for determining biomarkers of AD.....	376
<i>Gene expression patterns in AD</i> .....	376
<i>Magnetic resonance spectroscopy in AD</i> .....	377
<i>MicroRNAs as biomarkers of neurodegenerative disorders</i> .....	377
<i>MRI for biomarkers of AD</i> .....	378
<i>Nanotechnology to measure A<math>\beta</math>-derived diffusible ligands</i> .....	379
<i>PET scanning for biomarkers of AD</i> .....	379
<i>Simultaneous measurement of several biomarkers for AD</i> .....	381
<i>Targeting of chemokine receptor as biomarker for brain imaging</i> .....	381
Biomarkers of AD in CSF .....	382
<i>CSF sulfatide as a biomarker for AD</i> .....	382
<i>CSF Reelin as biomarker of AD</i> .....	382
<i>Monitoring of synthesis and clearance rates of A<math>\beta</math> in the CSF</i> .....	382
<i>Protein biomarkers of AD in CSF</i> .....	383
<i>Tau proteins in CSF</i> .....	384
<i>Tests for the detection of A<math>\beta</math> in CSF</i> .....	384
<i>Tests combining CSF tau and A<math>\beta</math></i> .....	385
Blood biomarkers of AD .....	386
<i>A serum protein-based algorithm for the detection of AD</i> .....	386
<i>Amyloid precursor protein</i> .....	386
<i>Detection of aggregated misfolded proteins in the blood</i> .....	386
<i>Lipid biomarkers for preclinical detection of AD</i> .....	387
<i>Lymphocyte Proliferation Test</i> .....	387
<i>Metabolomic biomarker profiling</i> .....	387
<i>Plasma protein biomarkers of AD</i> .....	387
<i>Protein kinase C in red blood cells</i> .....	388
Urine tests for AD .....	388
A biomarker-based skin test for AD .....	389
Salivary biomarkers of AD.....	389
Applications of biomarkers of AD.....	389
<i>Biomarker changes in autosomal dominantly inherited AD</i> .....	389
<i>Correlation of imaging biomarkers with CSF biomarkers of AD</i> .....	390
<i>Genetic tests for AD</i> .....	390

<i>Humanin as a biomarker as well as neuroprotective in AD</i> .....	391
<i>Plasma biomarkers of drug response in AD</i> .....	391
<i>PredictAD project</i> .....	391
<i>TOMM40 gene and risk of AD</i> .....	392
<i>Use of biomarkers to predict AD in patients with MCI</i> .....	392
Concluding remarks about biomarkers for AD and future prospects .....	393
<b>Biomarkers of Parkinson's disease .....</b>	<b>394</b>
Autoantibodies as biomarkers of PD .....	395
Biomarkers of PD based on gene expression in blood.....	395
Cardiac denervation as a biomarker of PD .....	395
Genetic biomarkers of PD.....	395
Imaging biomarkers of PD.....	396
Metabolic brain networks as biomarkers.....	397
Metabonomic biomarker profile for diagnosis and monitoring of PD .....	397
Protein biomarkers of PD .....	397
<i>P11 protein as a biomarker of depression in PD</i> .....	398
Serum vitamin D as a biomarker of PD .....	398
Biomarkers of prodromal PD.....	399
Future needs for biomarkers of PD .....	399
<b>Biomarkers of Huntington's disease .....</b>	<b>400</b>
Genetic biomarker of HD progression .....	401
Quantitative MRI measurement of brain atrophy as biomarker of HD .....	401
Metabolic networks as biomarkers of preclinical Huntington disease .....	401
<b>Biomarkers of Wilson's disease .....</b>	<b>402</b>
<b>Biomarkers of amyotrophic lateral sclerosis .....</b>	<b>402</b>
ALS biomarker detection in blood vs CSF .....	403
Biomarkers of neuroinflammation in ALS.....	403
Genetic biomarkers of ALS .....	403
Imaging biomarkers of ALS .....	404
Metabolomic biomarkers of ALS .....	404
Proteomic biomarkers of ALS.....	405
Ideal biomarker of ALS .....	405
Future of biomarkers of ALS .....	405
<b>HIV-1-associated neurocognitive disorders .....</b>	<b>406</b>
Biomarkers of dementia in HIV-1-infected patients.....	406
<b>Biomarkers of autoimmune encephalitis.....</b>	<b>406</b>
<b>Biomarkers of prion diseases.....</b>	<b>406</b>
14-3-3 protein and tTau/P-Tau ratio.....	407
Bioluminescence imaging as a surrogate biomarker of prion infectivity .....	407
miRNAs as biomarkers of prion-induced neurodegeneration .....	407
Prion protein detection by real-time quaking-induced conversion .....	408
Prions in the urine of patients with variant CJD .....	408
<b>Biomarkers of multiple sclerosis.....</b>	<b>408</b>
Antibodies in multiple sclerosis .....	409
<i>Antibodies to galactocerebroside</i> .....	410
<i>Antibodies to myelin oligodendrocyte glycoprotein</i> .....	410
Brain N-acetylaspartylglutamate as biomarker of cognitive function in MS.....	410
Brain imaging biomarkers of multiple sclerosis.....	410
<i>MRI biomarkers of multiple sclerosis</i> .....	410
<i>Molecular imaging</i> .....	411
Biomarkers of response to therapy of multiple sclerosis .....	411
<i>DNA motifs in the blood as biomarkers of response to treatment</i> .....	411
<i>Gene expression</i> .....	412
<i>Lymphocyte subsets as biomarkers of therapeutic response</i> .....	413
<i>Neurofilaments</i> .....	413
<i>Vitamin D as predictor of activity and progression of MS</i> .....	413
CSF biomarkers in multiple sclerosis.....	413
CSF Cystatin C as a biomarker of multiple sclerosis.....	413
Detecting autoantibodies in multiple sclerosis .....	414
<i>Switch-associated protein 70 antibodies in multiple sclerosis</i> .....	414
Gelsolin as a biomarker of multiple sclerosis.....	414
Matrix metalloproteinases as biomarkers in multiple sclerosis .....	414
Oligoclonal bands as biomarkers of MS .....	415
Serum proteomic pattern analysis in multiple sclerosis .....	415
T cells as biomarkers of multiple sclerosis .....	415
Concluding remarks and future perspective for biomarkers of multiple sclerosis.....	415
<b>Biomarkers of cerebrovascular disorders.....</b>	<b>416</b>
Biomarkers of stroke .....	416
<i>Etiological biomarkers of ischemic stroke</i> .....	418
<i>Brain natriuretic peptide as a biomarker for cardioembolic stroke</i> .....	419
<i>Brain lactate and N-acetylaspartate as biomarkers of stroke</i> .....	419

CRP as biomarker of risk of stroke .....	419
CSF biomarkers in acute stroke .....	420
Gene expression in blood following ischemic stroke .....	420
Glutathione S-Transferase-n .....	420
Intercellular adhesion molecule 1 as biomarker of ischemic stroke .....	421
Lp-PLA2 and CRP as biomarkers for stroke .....	421
Matrix metalloproteinase-9 .....	421
miRNAs as biomarkers of stroke .....	421
Neuroserpin polymorphisms as a biomarker of stroke .....	421
NMDA receptors as biomarkers of excitotoxicity in stroke .....	422
Nucleosomes as biomarkers of stroke .....	422
PARK7 and nucleoside diphosphate kinase A as biomarkers of stroke .....	422
Visinen-like protein 1 .....	423
Biomarker panels for stroke .....	423
Future prospects for biomarkers of stroke .....	423
Biomarkers of cerebral vasospasm .....	424
Biomarkers of intracerebral hemorrhage .....	424
Biomarkers of hypoxic brain damage .....	425
Biomarkers of ischemic brain damage .....	425
D-dimer as a biomarker of cerebral venous thrombosis .....	425
<b>Biomarkers of traumatic brain injury .....</b>	<b>426</b>
Technologies for identification of biomarkers of TBI .....	426
Cerebral microdialysis for study of biomarkers of TBI .....	426
Proteomic technologies for biomarkers of TBI .....	427
Systemy biology approach for discovery of biomarkers of TBI .....	428
Biomarkers of TBI .....	428
A $\beta$ as a biomarker of TBI .....	429
CCL11 as a biomarker of chronic traumatic encephalopathy .....	429
Diffusion tensor imaging in TBI .....	429
Glial fibrillary acidic protein as biomarker of TBI .....	429
Hyperphosphorylated axonal neurofilament protein .....	430
IL-6 and nerve growth factor as biomarkers of TBI .....	430
Myelin basic protein .....	430
Neurofilament heavy chain .....	430
Serum S100 $\beta$ as biomarker of TBI .....	431
SNTF as a biomarker for predicting cognitive decline after mild TBI .....	431
Tau as biomarker of TBI .....	432
Ubiquitin C-terminal Hydrolase-L1 .....	432
Biomarkers of inflicted TBI in infants .....	432
Biomarkers of concussion .....	433
Clinical applications of biomarkers of TBI .....	433
<b>Biomarkers of CNS infections .....</b>	<b>434</b>
Biomarkers of bacterial meningitis .....	434
Biomarkers of viral infections of CNS .....	434
Biomarkers of CNS HIV infection .....	434
CSF kynurenic acid level as a biomarker of tick-borne encephalitis .....	435
<b>Biomarkers of epilepsy .....</b>	<b>435</b>
Biochemical markers of epilepsy .....	436
Biomarkers of temporal lobe epilepsy .....	436
Biomarkers of drug-resistant epilepsy .....	436
Genetic epilepsies .....	437
Electrophysiological biomarkers of epilepsy .....	437
Imaging biomarkers of epilepsy .....	437
Protein biomarkers of inflammation in epilepsy .....	438
<b>Biomarkers of normal pressure hydrocephalus .....</b>	<b>438</b>
<b>Biomarkers of pseudotumor cerebri .....</b>	<b>438</b>
<b>Biomarkers of retinal disorders .....</b>	<b>439</b>
Biomarkers of age-related macular degeneration .....	439
<b>Biomarkers of sleep disorders .....</b>	<b>440</b>
Biomarker of excessive daytime sleepiness .....	440
Biomarkers of obstructive sleep apnea .....	440
Biomarkers of restless legs syndrome .....	441
<b>Biomarkers of pain .....</b>	<b>441</b>
Biomarkers of disorders with musculoskeletal pain .....	442
Biomarkers of neuropathic pain .....	442
Brain insular glutamate as biomarker of fibromyalgia .....	442
Biomarkers of visceral pain .....	442
Biomarkers of migraine .....	443
<b>Biomarkers of myalgic encephalomyelitis/chronic fatigue syndrome .....</b>	<b>443</b>
<b>Biomarkers of psychiatric disorders .....</b>	<b>444</b>
Anorexia nervosa .....	444



Attention-deficit hyperactivity disorder .....	445
Biomarkers of autism .....	445
<i>Epigenetics of ASD</i> .....	446
<i>Gastrointestinal microbiota disturbances and ASD</i> .....	446
<i>Genetic factors in ASD</i> .....	446
<i>Immune biomarkers of ASD</i> .....	446
<i>Metabolic disturbances in autism</i> .....	447
<i>Neurophysiological biomarkers</i> .....	447
<i>Role of oxidative stress in autism</i> .....	448
<i>Test for ASD based on a 55-gene expression panel</i> .....	448
<i>Umbilical cord biomarkers</i> .....	448
Biomarkers of bipolar disorder .....	448
Biomarkers of depression .....	449
<i>Biochemical biomarkers of depression</i> .....	450
<i>Biomarkers and response to antidepressant treatment</i> .....	450
<i>Cingulate cortex activity and response to antidepressants</i> .....	451
<i>Genetic biomarkers of response to antidepressants</i> .....	451
<i>Inflammatory biomarkers of depression and psychosis</i> .....	451
<i>P11 as a biomarker of depression</i> .....	452
<i>Panels of blood-based biomarkers for diagnosis of MDD</i> .....	452
<i>Plasma metabolomics for diagnosis of MDD</i> .....	452
<i>Post-partum depression</i> .....	452
Biomarkers of posttraumatic stress disorder .....	453
Biomarkers of psychosis .....	454
Biomarkers of schizophrenia .....	454
<i>Biomarkers of abnormalities of visual information processing</i> .....	455
<i>Genetic biomarkers of schizophrenia</i> .....	455
<i>Gene expression analysis of blood for biomarkers of schizophrenia</i> .....	455
<i>Metabolic biomarkers of schizophrenia</i> .....	456
<i>Proteomic studies for biomarkers of schizophrenia</i> .....	456
Biomarkers of suicide .....	456

## **15. Biomarkers of Cardiovascular Disorders ..... 459**

### **Epidemiology of cardiovascular disease.....459**

#### **Biomarkers of cardiovascular diseases .....459**

Biomarkers of acute myocardial infarction .....	461
Genetic biomarkers of cardiovascular disorders.....	461

#### **Methods for identification of cardiovascular biomarkers .....463**

Application of proteomics for biomarkers of cardiovascular disease .....	463
<i>Targeted MS-based pipeline approach</i> .....	463
<i>Cardiovascular disease biomarker panel</i> .....	464
Detection of biomarkers of myocardial infarction in saliva by a nanobiochip.....	464
Metabolomic technologies for biomarkers of myocardial ischemia .....	464
Imaging biomarkers of cardiovascular disease .....	464
<i>Annexin A5 as an imaging biomarker of cardiovascular disease</i> .....	465
<i>Cardiovascular MRI</i> .....	465
<i>Cardiovascular hybrid imaging</i> .....	465
<i>Myocardial perfusion imaging</i> .....	465
Implantable magnetic biosensors for detecting cardiac biomarkers.....	466

#### **Applications of biomarkers of cardiovascular disease.....466**

Biomarkers for ischemic heart disease and myocardial infarction .....	466
<i>Troponin</i> .....	467
<i>Natriuretic peptide</i> .....	468
<i>Copeptin</i> .....	469
<i>Creatine kinase muscle brain</i> .....	470
<i>miRNAs as biomarkers of acute coronary syndrome</i> .....	470
<i>Myoglobin</i> .....	470
<i>Fatty acid binding protein</i> .....	470
<i>Growth Differentiation Factor-15</i> .....	471
<i>High density lipoprotein 2</i> .....	471
<i>Cripto-1 as a biomarker of myocardial infarction</i> .....	471
<i>Cataract as a biomarker of ischemic heart disease</i> .....	471
<i>Plasma CD93 as a biomarker for coronary artery disease</i> .....	472
<i>Plasma fetuin-A levels and the risk of myocardial infarction</i> .....	472
<i>YKL-40 as an inflammatory biomarker in ischemic heart disease</i> .....	472
Biomarkers of cardiomyopathy .....	472
<i>miRNA biomarkers of peripartum cardiomyopathy</i> .....	472
<i>Takotsubo cardiomyopathy</i> .....	473
<i>Troponin T levels in hypertrophic cardiomyopathy</i> .....	473
Biomarkers of heart failure.....	473
<i>Annexin A5 for prognosis of heart failure</i> .....	473

<i>Angiogenesis biomarkers</i> .....	474
<i>β-2a protein as a biomarker of heart failure</i> .....	474
<i>Desmin</i> .....	474
<i>Galectin-3 as biomarker of acute heart failure</i> .....	474
<i>G protein-coupled receptor kinase-2 as biomarker of CHF</i> .....	475
<i>KIF6 gene as biomarker of heart failure</i> .....	475
<i>Metabolic biomarkers of heart failure</i> .....	476
<i>miRNA biomarkers of heart failure</i> .....	476
<i>Natriuretic peptide as biomarker of heart failure</i> .....	476
<i>Oxidative stress as biomarker of heart failure</i> .....	477
<i>Future prospects for biomarkers of heart failure</i> .....	477
Biomarkers for atherosclerosis .....	477
<i>9p21-3 locus and coronary atherosclerosis</i> .....	477
<i>Adipocyte enhancer-binding protein 1</i> .....	478
<i>Gene signatures on leucocytes as biomarkers of atherosclerosis</i> .....	478
<i>Ghrelin as a biomarker of atherosclerosis</i> .....	479
<i>Imaging biomarkers of hypercholesterolemia/atherosclerosis</i> .....	479
<i>Inflammatory biomarkers of atherosclerosis</i> .....	479
<i>Lipid-modified proteins as biomarkers of atherosclerosis</i> .....	479
<i>Lp-PLA2 as biomarker of atherosclerotic heart disease</i> .....	479
<i>Metabolomic profile in hypercholesterolemia</i> .....	480
<i>Nitric oxide impairment and atherosclerosis</i> .....	480
<i>Oxygen free radicals as biomarkers of atherosclerosis</i> .....	480
<i>Proteomic profiles of serum inflammatory biomarkers of atherosclerosis</i> .....	480
Biomarkers of coronary heart disease .....	481
<i>Apolipoproteins as risk factors for coronary heart disease</i> .....	481
<i>CRP as biomarker of risk for coronary heart disease</i> .....	481
<i>High level of blood ceramides as a biomarker of CHD</i> .....	482
<i>Impairment of EPCs by oxidative stress as a biomarker of disease</i> .....	482
<i>Role of TNF in acute coronary syndromes</i> .....	483
<i>Serum parathyroid hormone as biomarker of CHD</i> .....	483
<i>Serum stem cell factor as a biomarker of CHD</i> .....	483
<i>VILCAD biomarker score for prediction of long-term mortality in CHD</i> .....	483
Biomarkers for pulmonary arterial hypertension .....	484
Biomarkers of abdominal aortic aneurysm .....	484
<b>Biomarkers of thrombotic disorders</b> .....	<b>486</b>
Biomarkers of arterial thromboembolism .....	486
<i>Nanoparticles as synthetic biomarkers of thrombus formation</i> .....	486
Biomarkers of venous thromboembolism .....	486
<i>BNP and cTnT as biomarkers of outcome in pulmonary embolism</i> .....	486
<i>D-dimer as biomarker of venous thromboembolism</i> .....	487
<i>Molecular biomarkers of venous thromboembolism</i> .....	487
Genetic biomarkers for cardiovascular disease .....	487
<i>Biomarkers of inherited cardiomyopathies</i> .....	487
<i>Gene mutations in pulmonary arterial hypertension</i> .....	487
<i>Gene variant as a risk factor for sudden cardiac death</i> .....	488
<i>Genetic biomarkers of early onset myocardial infarction</i> .....	488
<i>Genetic biomarkers of atherosclerosis</i> .....	488
<i>IL-1 gene polymorphism as biomarker of cardiovascular disease</i> .....	489
<i>IL-6R signaling pathway and coronary heart disease</i> .....	489
<i>Kallikrein gene mutations in cardiovascular disease</i> .....	489
<i>Kallikrein gene and essential hypertension</i> .....	490
<i>Mutations in the low density lipoprotein receptor gene</i> .....	490
<i>Mutations within several genes that code for ion channel</i> .....	490
<i>Polymorphisms of the eNOS gene and angina pectoris</i> .....	491
<i>Lipoprotein (a) genetics</i> .....	491
<i>Polymorphisms in the apolipoprotein C gene</i> .....	491
<i>Polymorphisms in the apolipoprotein E gene</i> .....	492
<i>Polymorphism in the angiotensinogen gene</i> .....	492
Multiple biomarkers for prediction of death from cardiovascular disease .....	492
<b>Role of biomarkers in the management of cardiovascular disease</b> .....	<b>493</b>
Biomarkers in the diagnosis/prognosis of myocardial infarction .....	493
Biomarkers for prevention of cardiovascular disease .....	493
<i>C reactive protein as biomarker of response to statin therapy</i> .....	495
<i>HSP72 and eNOS as biomarkers of cardioprotective effect of HBO</i> .....	495
<i>Multimarker panel for prognosis in chronic heart failure</i> .....	496
<i>Molecular signature analysis in management of cardiovascular diseases</i> .....	496
<i>Presage ST2 Assay</i> .....	496
<i>Role of circulating biomarkers and mediators of cardiovascular dysfunction</i> .....	497
<i>Use of protein biomarkers for monitoring acute coronary syndromes</i> .....	497
<i>Use of biomarkers for prognosis of recurrent atrial fibrillation</i> .....	497

Use of multiple biomarkers for monitoring of cardiovascular disease.....	498
Use of biomarkers in the management of peripheral arterial disease .....	498
Use of biomarkers in the management of hypertension.....	498
<b>Systems approach to cardiovascular biomarker research .....</b>	<b>499</b>
<b>16. Biomarkers of Pulmonary Diseases .....</b>	<b>501</b>
<b>Introduction .....</b>	<b>501</b>
Association of biomarkers of inflammation with lung function in the elderly .....	501
Biomarkers of oxidative stress in lung diseases.....	502
Biomarkers of community-acquired pneumonia.....	502
Biomarkers of acute lung injury and respiratory distress syndrome .....	502
<i>Cytokine/chemokine biomarkers of SARS.....</i>	<i>502</i>
<i>Plasma biomarkers related to inflammation .....</i>	<i>503</i>
<i>Urinary NO as biomarker.....</i>	<i>503</i>
Biomarkers of interstitial lung disease .....	503
<i>Pulmonary surfactant proteins as biomarkers for lung diseases.....</i>	<i>503</i>
<i>Serum KL-6 as biomarker of interstitial lung disease .....</i>	<i>504</i>
Biomarkers of chronic obstructive pulmonary disease.....	504
<i>Alpha1-antitrypsin gene polymorphisms predisposing to emphysema .....</i>	<i>504</i>
<i>Biomarkers of extracellular matrix turnover in COPD .....</i>	<i>505</i>
<i>Biomarkers of lung failure in COPD.....</i>	<i>505</i>
<i>BNP as a biomarker of chronic pulmonary disease.....</i>	<i>505</i>
<i>Chromagranin A (CgA) as biomarker of airway obstruction in smokers.....</i>	<i>506</i>
<i>C-reactive protein as a biomarker of COPD.....</i>	<i>506</i>
<i>Gene expression profile in peripheral blood of patients with COPD.....</i>	<i>506</i>
<i>Hyperuricemia as a biomarker of early mortality in COPD.....</i>	<i>506</i>
<i>Increased expression of PIGF as a biomarker of COPD.....</i>	<i>506</i>
Biomarkers of asthma .....	507
<i>Biomarker for rhinovirus-induced asthma exacerbation.....</i>	<i>507</i>
<i>Biomarkers for predicting response to corticosteroid therapy .....</i>	<i>507</i>
<i>Comparison of biomarkers of asthma and COPD .....</i>	<i>507</i>
<i>Cytokines as biomarkers of asthma severity.....</i>	<i>508</i>
<i>Exhaled NO as a biomarker of asthma .....</i>	<i>508</i>
<i>Endothelin-1 in exhaled breath as biomarker of asthma.....</i>	<i>509</i>
<i>IgE as guide to dosing of omalizumab for asthma .....</i>	<i>509</i>
<i>Periostin as a biomarker for treatment of asthma with lebrikizumab .....</i>	<i>509</i>
Biomarkers of cystic fibrosis.....	510
<b>17. Biomarkers in Gynecology and Obstetrics .....</b>	<b>511</b>
<b>Introduction .....</b>	<b>511</b>
<b>Biomarkers of menopause .....</b>	<b>511</b>
<b>Biomarkers of premenstrual dysphoric disorder .....</b>	<b>511</b>
<b>Biomarkers of endometriosis .....</b>	<b>512</b>
<b>Biomarkers for preeclampsia .....</b>	<b>512</b>
Pathogenesis of preeclampsia.....	512
Metabolomic biomarkers in urine in preeclampsia.....	513
Protein biomarker of preeclampsia in urine.....	513
Protein biomarkers of preeclampsia in CSF.....	514
Protein HtrA1 as a biomarker for preeclampsia .....	514
Placental growth factor as a biomarker for preeclampsia .....	515
sFlt1 and soluble endoglin as biomarkers of preeclampsia .....	515
RNA biomarkers.....	515
Genes associated with preeclampsia.....	516
<b>Biomarkers of premature birth .....</b>	<b>516</b>
Proteomic biomarkers of premature birth .....	516
<b>Biomarkers of oxidative stress in complicated pregnancies.....</b>	<b>517</b>
<b>Fetal biomarkers in maternal blood .....</b>	<b>517</b>
<b>Metabolic biomarkers of prenatal disorders in the mother.....</b>	<b>518</b>
<b>18. Biomarkers &amp; Personalized Medicine .....</b>	<b>519</b>
<b>Introduction .....</b>	<b>519</b>
<b>Pharmacogenetics .....</b>	<b>519</b>
Biomarkers and pharmacogenetics.....	520
<b>Pharmacogenomics.....</b>	<b>521</b>
<b>Pharmacoproteomics .....</b>	<b>522</b>
Single cell proteomics for personalized medicine .....	522
<b>Role of biomarkers in development of personalized drugs.....</b>	<b>523</b>
Metabolomic biomarker-based drug discovery .....	523
Use of biomarkers for developing MAb therapy in oncology .....	523
<b>Biomarker tests for molecularly targeted therapies.....</b>	<b>524</b>
<b>Biobanking, biomarkers and personalized medicine in EU .....</b>	<b>525</b>

<b>Bioinformatics to sort biomarker data for personalized medicine .....</b>	<b>526</b>
<b>Biomarkers for monitoring response to therapy .....</b>	<b>527</b>
<b>Drug rescue by biomarker-based personalized medicine .....</b>	<b>527</b>
<b>Future role of biomarkers in personalized medicine .....</b>	<b>528</b>

<b>19. Biomarkers and Regulatory issues .....</b>	<b>529</b>
<b>Introduction .....</b>	<b>529</b>
<b>Biomarker validation .....</b>	<b>529</b>
FDA criteria for a valid biomarker .....	529
FDA letter of support for biomarkers .....	531
Role of NIST in validation of cancer biomarkers .....	532
Quality specifications for BNP and NT-proBNP as cardiac biomarker assays .....	532
National Biomarker Development Alliance .....	532
<b>FDA perspective of biomarkers in clinical trials .....</b>	<b>533</b>
<b>FDA and predictive medicine.....</b>	<b>534</b>
<b>Biomarkers and FDA's Voluntary Genomic Data Submission .....</b>	<b>535</b>
<b>Role of imaging biomarkers in approval of drugs.....</b>	<b>535</b>
<b>Regulatory oversight of biomarker tests for targeted therapies .....</b>	<b>536</b>
<b>FDA and biomarkers .....</b>	<b>536</b>
FDA consortium linking genetic biomarkers to serious adverse events .....	536
Oncology Biomarker Qualification Initiative .....	537
Critical Path Initiative .....	537
Predictive Safety Testing Consortium.....	539
The 21st Century Cures Act and biomarkers .....	539
From validated biomarker assay to a clinical laboratory diagnostic .....	540
Fast Path programs .....	541
Regulatory challenges in the biomarker field .....	541
FDA requirements of biomarkers and companion diagnostics .....	542
<b>20. References.....</b>	<b>543</b>

### Tables

Table 1-1: Historical landmarks in discovery and development of biomarkers .....	30
Table 1-2: Classification of biomarkers .....	30
Table 1-3: Terminology of clinically relevant biomarkers of disease .....	32
Table 1-4: Autoimmune disorders under study for autoantibodies as predictors .....	42
Table 1-5: Comparison of various types of biomarkers .....	42
Table 1-6: Various "omics" technologies for discovery of biomarkers .....	44
Table 1-7: Role of biomarkers in translational medicine .....	45
Table 2-1: Classification of methods of gene expression analysis .....	48
Table 2-2: Comparison of proteomic profiling technologies for discovery of biomarkers .....	74
Table 2-3: Companies involved in developing molecular imaging .....	85
Table 3-1: Applications of biochip/microarray technology in relation to biomarkers .....	107
Table 4-1: Companies using metabolomics for drug discovery .....	121
Table 4-2: Biomarker-based drug development at major pharmaceutical companies .....	122
Table 4-3: Causes of failures in clinical trials and their reduction by use of biomarkers .....	125
Table 5-1: Metabolic biomarkers of inflammatory diseases.....	139
Table 5-2: Oxidized phospholipids as biomarkers of various diseases .....	140
Table 5-3: Examples of biomarkers common to multiple diseases .....	154
Table 5-4: Examples of use of biomarkers in animal health .....	156
Table 6-1: Biomarkers of diabetes mellitus .....	160
Table 8-1: miRNAs deregulated in rheumatoid arthritic tissues .....	180
Table 8-2: Classification of inflammatory biomarkers in osteoarthritis.....	183
Table 9-1: Biomarkers of sepsis.....	192
Table 11-1: Biomarkers of aging.....	209
Table 12-1: Nutritional biomarkers.....	218
Table 13-1: Desirable characteristics of biomarkers for cancer .....	225
Table 13-2: Types of cancer biomarkers .....	227
Table 13-3: A classification of molecular diagnostic methods in cancer .....	234
Table 13-4: Cancer biomarkers used for diagnosis and therapy .....	264
Table 13-5: Novel biomarkers of prognosis in cancer treatment.....	269
Table 13-6: Biomarkers of brain tumors .....	277
Table 13-7: Biomarkers of breast cancer .....	285
Table 13-8: miRNA associated with breast cancer .....	294
Table 13-9: Biomarkers of colorectal cancer.....	304
Table 13-10: Biomarkers of lung cancer .....	318
Table 13-11: Classification of biomarkers of melanoma .....	327
Table 13-12: Biomarkers of nasopharyngeal carcinoma and potential applications .....	329

Table 13-13: Biomarkers of ovarian cancer .....	331
Table 13-14: Classification of biomarkers of pancreatic cancer .....	336
Table 13-15: Biomarkers of prostate cancer .....	341
Table 14-1: Biomarkers of cerebral metabolism .....	361
Table 14-2: Classification of biomarkers of Alzheimer disease in blood and CSF .....	374
Table 14-3: Characteristics of an ideal biomarker for Alzheimer disease .....	376
Table 14-4: miRNA expression in neurodegenerative diseases .....	377
Table 14-5: Biomarkers of Parkinson disease .....	394
Table 14-6: Biomarkers of Huntington disease .....	400
Table 14-7: Classification of biomarkers of amyotrophic lateral sclerosis .....	402
Table 14-8: Biomarkers of multiple sclerosis .....	408
Table 14-9: Gene expression as biomarker of response to interferon- $\beta$ in multiple sclerosis .....	412
Table 14-10: Biomarkers of stroke .....	417
Table 14-11: Etiological blood biomarkers of ischemic strokes due to large artery atherosclerosis .....	418
Table 14-12: Biomarkers of traumatic brain injury .....	428
Table 14-13: Biomarkers of epilepsy .....	435
Table 14-14: Biomarkers of autism spectrum disorder .....	445
Table 14-15: Biomarkers of response to antidepressant treatment .....	450
Table 14-16: Biomarkers of posttraumatic stress disorder .....	453
Table 15-1: Classification of biomarkers for cardiovascular diseases .....	460
Table 15-2: Genes that cause cardiovascular diseases .....	462
Table 15-3: Biomarkers of abdominal aortic aneurysm .....	485
Table 15-4: Biomarkers for cardiovascular disease risk prediction .....	493
Table 16-1: Biomarkers of pulmonary diseases .....	501
Table 18-1: Pharmacogenetic vs. pharmacogenomic studies .....	520
Table 18-2: Applications of pharmacoproteomic biomarkers in personalized medicine .....	522
Table 19-1: Issued letters of support for biomarkers by the FDA .....	531
Table 19-2: Drugs requiring biomarker/companion diagnostic information in the label .....	542

## Figures

Figure 1-1: Relation of biomarkers to other technologies and healthcare .....	45
Figure 1-2: Role of biomarkers in monitoring of diseases .....	46
Figure 2-1: The central role of spectrometry in proteomics .....	57
Figure 2-2: Selected reaction monitoring workflow for verification of biomarkers .....	71
Figure 4-1: Role of biomarkers in drug discovery and development process .....	111
Figure 4-2: Onion-peel model of biomarker development .....	126
Figure 5-1: Diseases associated with myositis autoantibodies .....	155
Figure 6-1: Plasma lipids in metabolic syndrome .....	166
Figure 8-1: $\beta$ -CrossLaps bone resorption biomarker assay .....	186
Figure 13-1: Role of proteomics in the discovery of cancer biomarkers .....	241
Figure 13-2: Nanowire biosensor for cancer diagnosis .....	257
Figure 13-3: Cancer biomarker development and validation .....	356
Figure 14-1: Discovery and application of biomarkers in neurological diseases .....	359
Figure 14-2: A scheme of pathogenesis of MDD with relevant biomarkers .....	450
Figure 15-1: Biomarkers of acute myocardial infarction related to pathophysiology .....	461
Figure 18-1: Role of pharmacogenetic biomarkers in personalized medicine .....	521
Figure 18-2: Workflow for developing metabolomics-based biomarkers for personalized treatment .....	523
Figure 18-3: Impact of biomarkers on personalized medicine .....	528
Figure 19-1: Stages and timelines of biomarker discovery, development and marketing .....	529
Figure 19-2: Biomarker qualification pilot process at the FDA .....	531
Figure 19-3: From a validated biomarker assay to a clinical laboratory diagnostic .....	540